Tofacitinib For Treatment Of Chronic Pouchitis

Part of paid clinical trials in Los Angeles, California.

Sponsor
Cedars-Sinai Medical Center
Study ID
NCT04580277
Phase
PHASE2
Status
Terminated

Conditions

  • Ileal Pouch
  • Ileal Pouchitis
  • Pouchitis

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Tofacitinib 10 mg — DRUG
    Subjects in this arm will receive tofactinib 10 mg twice daily for 8 weeks

Study Details

A phase 2 pilot study to evaluate the effectiveness of tofacitinib in subjects with chronic pouchitis

Key Dates

Start date
Jan 25, 2021
Status verified
Mar 2024
Primary completion
Dec 1, 2022
Completion
May 15, 2023

Study Design

Enrollment
6 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Chronic pouchitis
    This arm will include subjects with chronic pouchitis and will receive tofactinib 10 mg twice daily for 8 weeks

Primary Outcome Measure

Number of Participants With Clinical Response/Remission [ Time Frame: 8 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Cedars-Sinai Medical CenterLos AngelesCalifornia90048-

Find similar trials in Los Angeles, CA

By research site
Cedars-Sinai Medical Center· Los Angeles, CA

Related Studies